Literature DB >> 9387865

Brain-derived neurotrophic factor is reduced in Alzheimer's disease.

B Connor1, D Young, Q Yan, R L Faull, B Synek, M Dragunow.   

Abstract

Alzheimer's disease may be due to a deficiency in neurotrophin protein or receptor expression. Consistent with this hypothesis, a reduction in BDNF mRNA expression has been observed in human post-mortem Alzheimer's disease hippocampi. To further investigate this observation, we examined whether the alteration in BDNF expression also occurred at the protein level in human post-mortem Alzheimer's disease hippocampi and temporal cortices using immunohistochemical techniques. We observed a reduction in the intensity and number of BDNF-immunoreactive cell bodies within both the Alzheimer's disease hippocampus and temporal cortex when compared to normal tissue. These results support and extend previous findings that BDNF mRNA is reduced in the human Alzheimer's disease hippocampus and temporal cortex, and suggest that a loss of BDNF may contribute to the progressive atrophy of neurons in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9387865     DOI: 10.1016/s0169-328x(97)00125-3

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  172 in total

1.  Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood-brain barrier using focused ultrasound and microbubbles.

Authors:  Babak Baseri; James J Choi; Thomas Deffieux; Gesthimani Samiotaki; Yao-Sheng Tung; Oluyemi Olumolade; Scott A Small; Barclay Morrison; Elisa E Konofagou
Journal:  Phys Med Biol       Date:  2012-03-09       Impact factor: 3.609

2.  Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons.

Authors:  Liqi Tong; Robert Balazs; Phillip L Thornton; Carl W Cotman
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

Review 3.  Metabolic reserve as a determinant of cognitive aging.

Authors:  Alexis M Stranahan; Mark P Mattson
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease.

Authors:  Cunlu Xu; Zhenhua Wang; Ming Fan; Bing Liu; Ming Song; Xiantong Zhen; Tianzi Jiang
Journal:  Neuroreport       Date:  2010-08-23       Impact factor: 1.837

5.  Roles for gamma-aminobutyric acid in the development of the paraventricular nucleus of the hypothalamus.

Authors:  Kristy M McClellan; Matthew S Stratton; Stuart A Tobet
Journal:  J Comp Neurol       Date:  2010-07-15       Impact factor: 3.215

Review 6.  Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.

Authors:  I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira
Journal:  Neuromolecular Med       Date:  2015-09-15       Impact factor: 3.843

Review 7.  Progesterone, brain-derived neurotrophic factor and neuroprotection.

Authors:  M Singh; C Su
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

8.  Serum Markers of Neurodegeneration in Maple Syrup Urine Disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuk; Gustavo C Ferreira; Joao Seda Neto; Tatiana Amorin; Ida Vanessa D Schwartz; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  Differential cortical neurotrophin and cytogenetic adaptation after voluntary exercise in normal and amnestic rats.

Authors:  J M Hall; R P Vetreno; L M Savage
Journal:  Neuroscience       Date:  2013-11-09       Impact factor: 3.590

Review 10.  The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia.

Authors:  X Du; R A Hill
Journal:  J Mol Neurosci       Date:  2016-08-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.